Company
Codexis, Inc.
Headquarters: Redwood City, CA, United States
Founded: 2002
Employees: 261
CEO: Mr. John J. Nicols
Market Cap
$405.3 Million
USD as of Jan. 1, 2025
Codexis, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $74.2 M |
| EBITDA | $-37,664,500 |
| Gross Profit TTM | $57.3 M |
| Profit Margin | -87.73% |
| Operating Margin | -69.63% |
| Quarterly Revenue Growth | 31.50% |
Stocks & Indices
Codexis, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CDXS wb_incandescent
Stock: FSX: 4QK wb_incandescent
Key People
John J. Nicols (CEO and President) Ross Taylor (CFO)